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from 4–23 with the greatest variety in the mid-range. A small
number of proﬁles usually accounted for the majority that
occurred at each score. Differences in functioning were observed
across 2–5 ADLs at scores of 5–15 and 90–95, and across 7–9
ADLs at scores of 20–85. CONCLUSIONS: Only a fraction
(5%) of possible BI proﬁles occur clinically in stroke. Patients
with the same BI scores may vary in ADL functioning and require
different levels of clinical management. Depending on how ADLs
are valued, preferences for disability states within scores may
vary. In clinical trials, scores alone may not capture treatment
effects that are important to patients. Properly adapted, a 
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OBJECTIVES: To examine the relationship between health
insurance type and prescribed drug costs for orthopedic outpa-
tients of a regional hospital in southern Thailand. METHODS:
Electronic data for 3117 prescriptions for osteoarthritis (OA)
and rheumatoid arthritis (RA) new patients, whose age was 40
years or older and obtained their outpatient prescriptions from
October 1, 2001 to September 30, 2002, were analyzed. Descrip-
tive and linear regression analyses were used to analyze overall
and subgroup (OA and RA) data. RESULTS: Results showed
94.6% of the patients had osteoarthritis. They were divided into
three groups of health insurance type, which were Civil Servant
Medical Beneﬁt Scheme (CSMBS), Universal Coverage Scheme
(UC), and Social Security Scheme (SSS). While the SSS and UC
schemes paid by capitation basis, the CSMBS did by fee-for-
service basis. The CSMBS and SSS patients received higher
average cost per prescription and average cost per day than did
the UC patients. The RA patients obtained more expensive drugs
than did the OA patients. For OA patients, the CSMBS patients
had the lowest number of drugs per prescription. However, the
average cost per prescription and average cost per day of the
CSMBS and SSS patients were signiﬁcantly higher than those of
the UC patients. For RA patients, the average cost per prescrip-
tion and average cost per day of the UC patients were less than
those of the CSMBS and SSS patients, while their numbers of
drugs per prescription were slightly different. The regression
analysis for all patients and each subgroup showed signiﬁcant
relationship between the patients’ health insurance type and
average cost per prescription and average cost per day. CON-
CLUSIONS: A signiﬁcant relationship between the health insur-
ance type and prescription drug costs was found. The UC
patients tended to receive less expensive drugs than did the
others.
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OBJECTIVES: To promote rational drug use, governments may
apply various instruments to aid health care professionals in clin-
ical decision-making. Guidelines are a common approach, but
their impact on clinical practice is often limited. Therefore the
Dutch government sometimes applies a stronger instrument: con-
ditional reimbursement enforced by law, applied to drug groups
listed on the so-called “Annex 2”. We assessed process and 
outcomes of this instrument. METHODS: We quantitatively
explored the effects of conditional reimbursement on drug use
and costs for 33 Annex 2-drugs using the national GIP-database
that administers funding decisions for people in insurance
schemes. The qualitative process evaluation used document
analyses, interviews (N = 70), and case studies (N = 6) to map
perceptions of patients, physicians, pharmacists, insurers, man-
ufacturers, and policy makers to attain insights into the perfor-
mance of Annex 2. In focus groups we triangulated ﬁndings and
identiﬁed improvements. RESULTS: The quantitative analysis
showed that effects of conditional reimbursement varied with
type of conditions and clinical setting. People responsible for
implementation complained about administrative burden and
lack of means to monitor if conditions for reimbursement were
met (e.g. statins). An additional problem is that Annex 2 condi-
tions lag behind evolving clinical knowledge (e.g. clopidogrel).
The way in which conditions were operationalised appeared
crucial for their implementation. When stakeholders had been
actively involved in their operationalisation (e.g. TNF-b-block-
ers) implementation was successful, lack of consensus on the
conditions was detrimental to effectiveness of Annex 2 policy.
CONCLUSIONS: Overall, Annex 2 is considered a necessary
instrument, although there are conditions to be met for a more
effective functioning in the near future. There is a demand for
more dynamic and pro-active communication strategy by the dif-
ferent Annex 2-actors to increase awareness of the existing policy
and to narrow the gap between the clinical practice and policy
regarding registration and reimbursement of drugs.
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There is a global need for education in the ﬁeld of pharma-
coeconomics (PE). One is provided by Colleges of Pharmacy
(COP’s). Several surveys were conducted during the 1990’s to
determine the extent of pharmacoeconomic education at US-
based COP’s. One survey found that by 1999, 90% of US COP’s
provided PE education. On the other hand, only one study, con-
ducted in 1997, was found that surveyed Non-US COP’s. A total
of 112 Non-US COP’s in 44 countries were surveyed via e-mail;
41 COP’s from 25 countries responded. Seventeen COP’s from
13 countries reported providing PE education. OBJECTIVE: The
objective of this study was to perform a follow-up study for Non-
US COP’s. METHODS: During January—May, 2004, surveys
were sent to 291 Non-US COP’s in 42 countries via e-mail using
information from the World List of Pharmacy Schools (WLPS).
Follow-up e-mails were sent to non-respondents and to respon-
dents when clariﬁcations of their responses were needed.
RESULTS: A total of 89 COP’s from 42 countries provided
usable responses. A total of 46 COP’s from 28 countries indi-
cated that they provided PE education. Of these 46 COP’s, nine
provided education at the professional level only, 15 at the grad-
uate level only and 22 at both levels. The median number of stu-
dents enrolled at the professional level was 100, and 15 at the
graduate level. The median number of class contact hours for PE
education was 12 for professional students and 15 for graduate
students. CONCLUSIONS: Fifty-one percent (51%)of respon-
dents provided PE education compared to 41% from the 1997
survey. The majority of Non-US COP’s that offered PE educa-
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tion were located in Europe (N = 19), followed by Asia (N = 9),
North America (N = 7), and Oceania (N = 6). More research is
needed to determine the extent of PE education from other
sources (e.g. other disciplines and non-university based).
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Prior to patent expiry of a drug, the manufacturer will generally
increase marketing efforts in order to maintain market-share.
The introduction of generics will lead to strong competition,
forcing the original patent holder to change their marketing
strategy. These effects, together with other factors (e.g. govern-
mental price legislation) may lead to increasing drug expendi-
tures. In order to increase price competition the Dutch
government plans to modernize the drug reimbursement system,
which is conceived to inadequately control drug prices. In par-
ticular, drug prices may not relevantly decrease due to lack of
incentives for price competition. OBJECTIVES: To investigate
the magnitude of effects on market-share and drug prices, we
evaluated trends in drug volume and costs after patent expiry for
enalapril, ﬂuoxetine and ranitidine in the The Netherlands.
METHODS: Governmental price, volume and reimbursement
policies were evaluated in order to provide a framework for
developments after patent expiry. Drug use was measured as
Deﬁned Daily Doses (DDD) per 1000 population, derived from
the InterAction DataBase, comprising pharmacies in the North
of the The Netherlands. Drug costs were calculated per DDD.
Estimated trendlines for drug costs and share of drugs in the dif-
ferent trade-channels (specialité, parallel, generic) were com-
pared. RESULTS: After the patent expired, costs per DDD—for
enalapril, ﬂuoxetine and ranitidine—decreased with 61%, 51%
and 69% respectively. For enalapril and ﬂuoxetine statistical sig-
niﬁcant differences in trendlines were found. For all investigated
drugs, generic products rapidly took over the majority of the
market-share (over 75%). Nearly all new users received a generic
drug after patent expiry. Further results will be presented on
omeprazol and simvastatine, with very recent patent expiries.
CONCLUSIONS: Our ﬁndings indicate that patent expiry may
cause price competition leading to cost decreases. This is oppo-
site the current opinion that the drug reimbursement system
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OBJECTIVES: To assess the health related quality of life in
common neuromuscular disease. METHODS: The health related
quality of life (HrQol) of 73 patients (mean age: 54.0 ± 16.9;
w/m: 41 :32) with Amyotrophic Lateral Sclerosis (ALS, n = 25),
Myasthenia Gravis (MSG, n = 32) or Facioscapulohumeral Mus-
cular Dystrophy (FSHD, n = 16) has been assessed using the SF-
36 and the EQ-5D. RESULTS: Measuring the HrQol using the
EQ-5D for the three diseases the overall score differs slightly
depending on sex (female 0.79 ± 0.22, male 0.66 ± 0.29). In con-
trast the disease speciﬁc overall score for patients with ALS was
0.53 ± 0.28, with FSHD 0.78 ± 0.13 and for patients with MSG
0.87 ± 0.19. This distribution was also true for the VAS (ALS
37.5 ± 13.59 FSHD 59.06 ± 17.91, MSG 65.63 ± 24.02). The
results of the SF 36 (n = 72) subscale bodily pain and mental
health for the three subgroups were not different. Differences
were found for the subscales physical function (ALS 41 ± 31,
FSHD 45 ± 35, MSG 72 ± 29), role limitations due to physical
problems (ALS 2 ± 7, FSHD 40 ± 43, MSG 49 ± 51), general
health perceptions (ALS 31 ± 14, FSHD 52 ± 21, MSG 39 ± 49),
vitality (ALS 37 ± 15, FSHD 52 ± 21, MSG 44 ± 44), social func-
tioning (ALS 56 ± 29, FSHD 82 ± 16, MSG 81 ± 25) and role
limitations due to emotional problems (ALS 24 ± 60, FSHD 81
± 34, MSG 65 ± 58). The results that the physical functioning
of the ALS and FSHD patients are similar, but the general health
perception of the FSHD patients needs further evaluation. An
additional aspect is the strong role limitation due to emotional
problems of ALS patients. CONCLUSIONS: Neuromuscular
diseases have a considerable impact on health-related quality of
life. Patients with ALS and FSHD have diminished scores in the
EQ-5D overall score and in the VAS. The SF-36 reﬂects in more
detail the inﬂuence of the three diseases on the different dimen-
sions of health-related quality of life.
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OBJECTIVES: Patients refractory to initial anti epileptic drugs
(AEDs) monotherapy may undergo a change in their therapeu-
tic regimen. This study sought to compare the economic costs of
care of patients refractory to initial AED therapy that was not
oxcarbazepine (Trileptal®), who were switched to oxcar-
bazepine (OXC) monotherapy and who stayed on OXC for an
entire 12 months follow-up (Cohort A), compared with the costs
of the patients who failed to be on the same therapy within one
year (Cohort B). METHODS: Retrospective data from the Phar-
Metrics integrated medical and pharmacy claims database,
which includes 57 managed care plans, were analyzed. Adult
patients receiving treatment with AEDs between January 1, 2000
and March 30, 2002 were studied. Data were analyzed from 6
months prior to treatment failure with either carbamazepine,
phenytoin, or valproic acid, and through a post-therapy period
deﬁned as 12 months after switching to OXC monotherapy.
RESULTS: 169 adult patients were observed. 31.4% (53/169)
patients stayed on OXC for an entire year of follow-up, consti-
tuting Cohort A. 116 patients (Cohort B) either switched to
another drug or opted for a combination therapy at some point
within one year. Demographic and clinical characteristics were
statistically similar between cohorts. Although pre-index treat-
ment costs are similar between the two cohorts ($9434 +SD
$14,512 versus $9430 + $15,229), the mean cost of care in
Cohort A decreased by $1123 while the mean cost rose for
Cohort B during the post-failure period (p < 0.01). Post-failure
